MedPanel Adds New Oncology Study

US healthcare MR company MedPanel has added a new area to its Profiles in Oncology series. The new study - focusing on the increasingly common disease of non-Hodgkin's lymphoma - will evaluate clinical and market opportunities for treatments, based on research among US and European medical professionals.

The study sets out to analyse unmet therapeutic needs and the product attributes that drive physician preference and prescribing behaviour.

The analysis is based on surveys conducted with hundreds of community-based practitioners, together with online, interactive discussions with academic and clinical specialists.

Subscribers to the study can manipulate the data, allowing them, for example, to assess and quantify the impact of different clinical trial results.

The incidence of non-Hodgkin's lymphoma has increased in recent decades, and is now the fifth most common cancer in the US. France, Germany, Italy, Spain, and the United Kingdom have among the largest numbers of cases in the world.

Matt Fearer, MedPanel's Senior VP of Content Development, believes the new study should 'prove invaluable to drug makers as they attempt to develop therapeutic agents with improved performance'.

MedPanel is online at www.medpanel.com.

All articles 2006-23 written and edited by Mel Crowther and/or Nick Thomas, 2024- by Nick Thomas, unless otherwise stated.